Detalhe da pesquisa
1.
New synthetic molecules incorporated into polymeric micelles used for treatment against visceral leishmaniasis.
Cytokine
; 177: 156543, 2024 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38373365
2.
Treatment using vanillin-derived synthetic molecules incorporated into polymeric micelles is effective against infection caused by Leishmania amazonensis species.
Exp Parasitol
; 260: 108743, 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513973
3.
Exploring drug repositioning for leishmaniasis treatment: Ivermectin plus polymeric micelles induce immunological response and protection against tegumentary leishmaniasis.
Cytokine
; 164: 156143, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36774730
4.
In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasis.
Exp Parasitol
; 251: 108555, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37247802
5.
Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis.
Parasitol Res
; 122(12): 2917-2931, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37768367
6.
Recombinant guanosine-5'-triphosphate (GTP)-binding protein associated with Poloxamer 407-based polymeric micelles protects against Leishmania infantum infection.
Cytokine
; 153: 155865, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35339043
7.
Leishmania LiHyC protein is immunogenic and induces protection against visceral leishmaniasis.
Parasite Immunol
; 44(8): e12921, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35437797
8.
Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary study.
Exp Parasitol
; 233: 108205, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34968460
9.
A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
Cell Immunol
; 356: 104194, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32827943
10.
Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasis.
Parasite Immunol
; 42(12): e12784, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32772379
11.
Serodiagnosis of paucibacillary and multibacillary leprosy using a recombinant chimeric protein composed of specific B-cell epitopes derived from Mycobacterium leprae proteins.
Tuberculosis (Edinb)
; 147: 102505, 2024 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38583359
12.
A recombinant chimeric antigen constructed with B-cell epitopes from Mycobacterium leprae hypothetical proteins is effective for the diagnosis of leprosy.
Diagn Microbiol Infect Dis
; 109(3): 116338, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38718661
13.
Immunotherapy Using Immunogenic Mimotopes Selected by Phage Display plus Amphotericin B Inducing a Therapeutic Response in Mice Infected with Leishmania amazonensis.
Pathogens
; 12(2)2023 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36839586
14.
Efficacy of an Immunotherapy Combining Immunogenic Chimeric Protein Plus Adjuvant and Amphotericin B against Murine Visceral Leishmaniasis.
Biology (Basel)
; 12(6)2023 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37372136
15.
The association between rLiHyp1 protein plus adjuvant and amphotericin B is an effective immunotherapy against visceral leishmaniasis in mice.
Acta Trop
; 246: 106986, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37453579
16.
Recombinant endonuclease III protein from Leishmania infantum associated with Th1-type adjuvants is immunogenic and induces protection against visceral leishmaniasis.
Mol Immunol
; 155: 79-90, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36731193
17.
B-Cell Epitopes-Based Chimeric Protein from SARS-CoV-2 N and S Proteins Is Recognized by Specific Antibodies in Serum and Urine Samples from Patients.
Viruses
; 15(9)2023 09 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37766284
18.
A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against Leishmania infantum Infection.
Vaccines (Basel)
; 10(7)2022 Jul 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35891310
19.
A recombinant Leishmania amastigote-specific protein, rLiHyG, with adjuvants, protects against infection with Leishmania infantum.
Acta Trop
; 230: 106412, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35305943
20.
Leishmania infantum pyridoxal kinase evaluated in a recombinant protein and DNA vaccine to protects against visceral leishmaniasis.
Mol Immunol
; 124: 161-171, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32585510